Genextra

InnovHeart is a medical device company that develops transcatheter mitral valve replacement systems to treat mitral valve disease. Its implant technology is designed to replace diseased mitral valves using a transcatheter approach, enabling hospitals to perform safer and more accessible valve replacement procedures. The company aims to provide a safe, effective, and easy-to-use solution for patients suffering from mitral valve dysfunction.

InnovHeart is a medical device company that develops transcatheter mitral valve replacement systems to treat mitral valve disease. Its implant technology is designed to replace diseased mitral valves using a transcatheter approach, enabling hospitals to perform safer and more accessible valve replacement procedures. The company aims to provide a safe, effective, and easy-to-use solution for patients suffering from mitral valve dysfunction.

EryDel, based in Urbino, has developed a patented technology for drug delivery utilizing erythrocytes, or red blood cells. This innovative approach enables the efficient loading of red blood cells with various therapeutic agents, including drugs, proteins, and nanoparticles, which can be gradually released into the patient's body. The technology enhances treatment efficacy while minimizing side effects, particularly for chronic conditions that typically require daily medication. EryDel's solution has undergone testing in patients suffering from Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. Additionally, the company provides comprehensive support for the drug delivery process through its specialized device, the "Red Cell Loader," and associated disposable kits. This system aims to streamline blood processing at the point of care, enabling healthcare professionals to deliver therapies for a range of conditions efficiently.

EryDel, based in Urbino, has developed a patented technology for drug delivery utilizing erythrocytes, or red blood cells. This innovative approach enables the efficient loading of red blood cells with various therapeutic agents, including drugs, proteins, and nanoparticles, which can be gradually released into the patient's body. The technology enhances treatment efficacy while minimizing side effects, particularly for chronic conditions that typically require daily medication. EryDel's solution has undergone testing in patients suffering from Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. Additionally, the company provides comprehensive support for the drug delivery process through its specialized device, the "Red Cell Loader," and associated disposable kits. This system aims to streamline blood processing at the point of care, enabling healthcare professionals to deliver therapies for a range of conditions efficiently.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.